{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T03:54:15Z","timestamp":1783050855272,"version":"3.54.6"},"reference-count":117,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,29]]},"DOI":"10.7759\/cureus.87002","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T03:44:48Z","timestamp":1751255088000},"source":"Crossref","is-referenced-by-count":1,"title":["Expert Consensus Statement on Simplified Glycemic Care in Patients With Type 2 Diabetes Mellitus"],"prefix":"10.7759","author":[{"given":"Bipin","family":"Sethi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhankar","family":"Chowdhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil M","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul Hamid","family":"Zargar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoj","family":"Chadha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arpandev","family":"Bhattacharyya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shehla","family":"Shaikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brij Mohan","family":"Makkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoj","family":"Chawla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pramila","family":"Kalra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishi","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sailesh","family":"Lodha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sambit","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuj","family":"Maheshwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surya K","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KM","family":"Suryanarayana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayashree","family":"Swain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin R","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoj Kumar","family":"Shrivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilakshi","family":"Deka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Jiwane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onkar C","family":"Swami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"The Diabetes Atlas. (2021). Accessed. Sep 19, 2024: https:\/\/diabetesatlas.org."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(23)00119-5","article-title":"Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17)","volume":"11","author":"Anjana RM","year":"2023","unstructured":"Anjana RM, Unnikrishnan R, Deepa M, et al.. Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17). Lancet Diabetes Endocrinol. 2023, 11:474-89. 10.1016\/S2213-8587(23)00119-5","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-29978-y","article-title":"Socioeconomic inequality in awareness, treatment and control of diabetes among adults in India: evidence from National Family Health Survey of India (NFHS), 2019-2021","volume":"13","author":"Maiti S","year":"2023","unstructured":"Maiti S, Akhtar S, Upadhyay AK, Mohanty SK. Socioeconomic inequality in awareness, treatment and control of diabetes among adults in India: evidence from National Family Health Survey of India (NFHS), 2019-2021. Sci Rep. 2023, 13:2971. 10.1038\/s41598-023-29978-y","journal-title":"Sci Rep"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-023-15661-4","article-title":"Epidemiology of type 2 diabetes mellitus and treatment utilization patterns among the elderly from the first wave of Longitudinal Aging study in India (2017-18)using a Heckman selection model","volume":"23","author":"Barman P","year":"2023","unstructured":"Barman P, Das M, Verma M. Epidemiology of type 2 diabetes mellitus and treatment utilization patterns among the elderly from the first wave of Longitudinal Aging study in India (2017-18)using a Heckman selection model. BMC Public Health. 2023, 23:699. 10.1186\/s12889-023-15661-4","journal-title":"BMC Public Health"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.4103\/ijo.IJO_1627_21","article-title":"Epidemiology of type 2 diabetes in India","volume":"69","author":"Pradeepa R","year":"2021","unstructured":"Pradeepa R, Mohan V. Epidemiology of type 2 diabetes in India. Indian J Ophthalmol. 2021, 69:2932-8. 10.4103\/ijo.IJO_1627_21","journal-title":"Indian J Ophthalmol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s13410-020-00838-z","article-title":"Economic menace of diabetes in India: a systematic review","volume":"40","author":"Oberoi S","year":"2020","unstructured":"Oberoi S, Kansra P. Economic menace of diabetes in India: a systematic review. Int J Diabetes Dev Ctries. 2020, 40:464-75. 10.1007\/s13410-020-00838-z","journal-title":"Int J Diabetes Dev Ctries"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-019-01295-9","article-title":"The prevalence of comorbid depression in patients with type 2 diabetes: an updated systematic review and meta-analysis on huge number of observational studies","volume":"56","author":"Khaledi M","year":"2019","unstructured":"Khaledi M, Haghighatdoost F, Feizi A, Aminorroaya A. The prevalence of comorbid depression in patients with type 2 diabetes: an updated systematic review and meta-analysis on huge number of observational studies. Acta Diabetol. 2019, 56:631-50. 10.1007\/s00592-019-01295-9","journal-title":"Acta Diabetol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1080\/21642850.2024.2324091","article-title":"Prevalence of diabetes distress among type 2 diabetes mellitus patients in India: a systematic review and meta-analysis","volume":"12","author":"Sinha R","year":"2024","unstructured":"Sinha R, Priya A, Sinha A, Hifz Ur Rahman M. Prevalence of diabetes distress among type 2 diabetes mellitus patients in India: a systematic review and meta-analysis. Health Psychol Behav Med. 2024, 12:2324091. 10.1080\/21642850.2024.2324091","journal-title":"Health Psychol Behav Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s13410-022-01129-5","article-title":"RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2022","volume":"42","year":"2022","unstructured":"RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2022. Int J Diabetes Dev Ctries. 2022, 42.1-143. 10.1007\/s13410-022-01129-5","journal-title":"Int J Diabetes Dev Ctries"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2024","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2024","unstructured":"American Diabetes Association Professional Practice Committee. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2024. Diabetes Care. 2024, 47:S158-78. 10.2337\/dc24-S009","journal-title":"Diabetes Care"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2337\/dci22-0034","article-title":"Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"45","author":"Davies MJ","year":"2022","unstructured":"Davies MJ, Aroda VR, Collins BS, et al.. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022, 45:2753-86. 10.2337\/dci22-0034","journal-title":"Diabetes Care"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0250993","article-title":"Regimen simplification and medication adherence: fixed-dose versus loose-dose combination therapy for type 2 diabetes","volume":"16","author":"B\u00f6hm AK","year":"2021","unstructured":"B\u00f6hm AK, Schneider U, Aberle J, Stargardt T. Regimen simplification and medication adherence: fixed-dose versus loose-dose combination therapy for type 2 diabetes. PLoS One. 2021, 16:e0250993. 10.1371\/journal.pone.0250993","journal-title":"PLoS One"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.4103\/jfmpc.jfmpc_843_20","article-title":"Fixed-dose combination in management of type 2 diabetes mellitus: expert opinion from an international panel","volume":"9","author":"Kalra S","year":"2020","unstructured":"Kalra S, Das AK, Priya G, et al.. Fixed-dose combination in management of type 2 diabetes mellitus: expert opinion from an international panel. J Family Med Prim Care. 2020, 9:5450-7. 10.4103\/jfmpc.jfmpc_843_20","journal-title":"J Family Med Prim Care"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.4103\/jod.jod_93_23","article-title":"Diabetes and current Indian scenario: a narrative review","volume":"15","author":"Muralidharan S","year":"2024","unstructured":"Muralidharan S. Diabetes and current Indian scenario: a narrative review. J Diabetol. 2024, 15:12-7. 10.4103\/jod.jod_93_23","journal-title":"J Diabetol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcd.2019.05.001","article-title":"The health effects of medical nutrition therapy by dietitians in patients with diabetes: a systematic review and meta-analysis: nutrition therapy and diabetes","volume":"13","author":"Razaz JM","year":"2019","unstructured":"Razaz JM, Rahmani J, Varkaneh HK, Thompson J, Clark C, Abdulazeem HM. The health effects of medical nutrition therapy by dietitians in patients with diabetes: a systematic review and meta-analysis: nutrition therapy and diabetes. Prim Care Diabetes. 2019, 13:399-408. 10.1016\/j.pcd.2019.05.001","journal-title":"Prim Care Diabetes"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.13429","article-title":"ISPAD Clinical Practice Consensus Guidelines 2022: nutritional management in children and adolescents with diabetes","volume":"23","author":"Annan SF","year":"2022","unstructured":"Annan SF, Higgins LA, Jelleryd E, et al.. ISPAD Clinical Practice Consensus Guidelines 2022: nutritional management in children and adolescents with diabetes. Pediatr Diabetes. 2022, 23:1297-321. 10.1111\/pedi.13429","journal-title":"Pediatr Diabetes"},{"key":"ref17","article-title":"Dietary Guidelines for Indians. [Internet].","author":"ICMR-NIN Expert Committee","year":"2024","unstructured":"ICMR-NIN Expert Committee. Dietary Guidelines for Indians. ICMR-National Institute of Nutrition, Hyderabad, India; 2024. https:\/\/www.nin.res.in\/dietaryguidelines\/pdfjs\/locale\/DGI07052024P.pdf."},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajcnut.2023.08.022","article-title":"The effectiveness of medical nutrition therapy provided by a dietitian in adults with prediabetes: a systematic review and meta-analysis","volume":"118","author":"Dudzik JM","year":"2023","unstructured":"Dudzik JM, Senkus KE, Evert AB, Raynor HA, Rozga M, Handu D, Moloney LM. The effectiveness of medical nutrition therapy provided by a dietitian in adults with prediabetes: a systematic review and meta-analysis. Am J Clin Nutr. 2023, 118:892-910. 10.1016\/j.ajcnut.2023.08.022","journal-title":"Am J Clin Nutr"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3390\/antiox12040904","article-title":"Comprehensive approach to medical nutrition therapy in patients with type 2 diabetes mellitus: from diet to bioactive compounds","volume":"12","author":"Barrea L","year":"2023","unstructured":"Barrea L, Vetrani C, Verde L, et al.. Comprehensive approach to medical nutrition therapy in patients with type 2 diabetes mellitus: from diet to bioactive compounds. Antioxidants (Basel). 2023, 12:904. 10.3390\/antiox12040904","journal-title":"Antioxidants (Basel)"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-056108","article-title":"Short-term effectiveness of nutrition therapy to treat type 2 diabetes in low-income and middle-income countries: systematic review and meta-analysis of randomised controlled trials","volume":"12","author":"Guilbert E","year":"2022","unstructured":"Guilbert E, Perry R, Whitmarsh A, Sauchelli S. Short-term effectiveness of nutrition therapy to treat type 2 diabetes in low-income and middle-income countries: systematic review and meta-analysis of randomised controlled trials. BMJ Open. 2022, 12:e056108. 10.1136\/bmjopen-2021-056108","journal-title":"BMJ Open"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s42000-023-00483-1","article-title":"A roadmap to medical nutrition therapy in type 2 diabetes","volume":"22","author":"Shalit A","year":"2023","unstructured":"Shalit A, Paschou SA, Psaltopoulou T. A roadmap to medical nutrition therapy in type 2 diabetes. Hormones (Athens). 2023, 22:633-5. 10.1007\/s42000-023-00483-1","journal-title":"Hormones (Athens)"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-0872-8","article-title":"Insights on medical nutrition therapy for type 2 diabetes mellitus: an Indian perspective","volume":"36","author":"Viswanathan V","year":"2019","unstructured":"Viswanathan V, Krishnan D, Kalra S, et al.. Insights on medical nutrition therapy for type 2 diabetes mellitus: an Indian perspective. Adv Ther. 2019, 36:520-47. 10.1007\/s12325-019-0872-8","journal-title":"Adv Ther"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s40279-018-0864-x","article-title":"The effects of postprandial exercise on glucose control in individuals with type 2 diabetes: a systematic review","volume":"48","author":"Borror A","year":"2018","unstructured":"Borror A, Zieff G, Battaglini C, Stoner L. The effects of postprandial exercise on glucose control in individuals with type 2 diabetes: a systematic review. Sports Med. 2018, 48:1479-91. 10.1007\/s40279-018-0864-x","journal-title":"Sports Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.576","article-title":"Physical activity advice only or structured exercise training and association with HbA1c levels in type 2 diabetes: a systematic review and meta-analysis","volume":"305","author":"Umpierre D","year":"2011","unstructured":"Umpierre D, Ribeiro PA, Kramer CK, et al.. Physical activity advice only or structured exercise training and association with HbA1c levels in type 2 diabetes: a systematic review and meta-analysis. JAMA. 2011, 305:1790-9. 10.1001\/jama.2011.576","journal-title":"JAMA"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-1881","article-title":"Effects of exercise on cardiovascular risk factors in type 2 diabetes: a meta-analysis","volume":"34","author":"Chudyk A","year":"2011","unstructured":"Chudyk A, Petrella RJ. Effects of exercise on cardiovascular risk factors in type 2 diabetes: a meta-analysis. Diabetes Care. 2011, 34:1228-37. 10.2337\/dc10-1881","journal-title":"Diabetes Care"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-014-3303-z","article-title":"Impact of different training modalities on glycaemic control and blood lipids in patients with type 2 diabetes: a systematic review and network meta-analysis","volume":"57","author":"Schwingshackl L","year":"2014","unstructured":"Schwingshackl L, Missbach B, Dias S, K\u00f6nig J, Hoffmann G. Impact of different training modalities on glycaemic control and blood lipids in patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetologia. 2014, 57:1789-97. 10.1007\/s00125-014-3303-z","journal-title":"Diabetologia"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.2337\/dc07-0048","article-title":"Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial","volume":"30","author":"Pi-Sunyer X","year":"2007","unstructured":"Pi-Sunyer X, Blackburn G, Brancati FL, et al.. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care. 2007, 30:1374-83. 10.2337\/dc07-0048","journal-title":"Diabetes Care"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-2073","article-title":"Sleep duration and risk of type 2 diabetes: a meta-analysis of prospective studies","volume":"38","author":"Shan Z","year":"2015","unstructured":"Shan Z, Ma H, Xie M, et al.. Sleep duration and risk of type 2 diabetes: a meta-analysis of prospective studies. Diabetes Care. 2015, 38:529-37. 10.2337\/dc14-2073","journal-title":"Diabetes Care"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.cegh.2020.03.006","article-title":"The impact of sleep duration and sleep quality on glycaemic control in Asian population with type 2 diabetes mellitus: a systematic literature review and meta-analysis of observational studies","volume":"1","author":"Azharuddin M","year":"2020","unstructured":"Azharuddin M, Kapur P, Adil M, et al.. The impact of sleep duration and sleep quality on glycaemic control in Asian population with type 2 diabetes mellitus: a systematic literature review and meta-analysis of observational studies. CEGH. 2020, 1:967-75. 10.1016\/j.cegh.2020.03.006","journal-title":"CEGH"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.smrv.2016.02.001","article-title":"The impact of sleep amount and sleep quality on glycemic control in type 2 diabetes: a systematic review and meta-analysis","volume":"31","author":"Lee SW","year":"2017","unstructured":"Lee SW, Ng KY, Chin WK. The impact of sleep amount and sleep quality on glycemic control in type 2 diabetes: a systematic review and meta-analysis. Sleep Med Rev. 2017, 31:91-101. 10.1016\/j.smrv.2016.02.001","journal-title":"Sleep Med Rev"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12854","article-title":"Understanding and overcoming metformin gastrointestinal intolerance","volume":"19","author":"Bonnet F","year":"2017","unstructured":"Bonnet F, Scheen A. Understanding and overcoming metformin gastrointestinal intolerance. Diabetes Obes Metab. 2017, 19:473-81. 10.1111\/dom.12854","journal-title":"Diabetes Obes Metab"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-S003","article-title":"3. Prevention or delay of diabetes and associated comorbidities: standards of care in diabetes-2024","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2024","unstructured":"American Diabetes Association Professional Practice Committee. 3. Prevention or delay of diabetes and associated comorbidities: standards of care in diabetes-2024. Diabetes Care. 2024, 47:S43-51. 10.2337\/dc24-S003","journal-title":"Diabetes Care"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.46108","article-title":"The effectiveness of metformin in diabetes prevention: a systematic review and meta-analysis","volume":"15","author":"Patel D","year":"2023","unstructured":"Patel D, Ayesha IE, Monson NR, Klair N, Patel U, Saxena A, Hamid P. The effectiveness of metformin in diabetes prevention: a systematic review and meta-analysis. Cureus. 2023, 15:e46108. 10.7759\/cureus.46108","journal-title":"Cureus"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-019-0900-7","article-title":"Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis","volume":"18","author":"Han Y","year":"2019","unstructured":"Han Y, Xie H, Liu Y, Gao P, Yang X, Shen Z. Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis. Cardiovasc Diabetol. 2019, 18:96. 10.1186\/s12933-019-0900-7","journal-title":"Cardiovasc Diabetol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.559446","article-title":"Metformin use and risk of all-cause mortality and cardiovascular events in patients with chronic kidney disease-a systematic review and meta-analysis","volume":"11","author":"Hu Y","year":"2020","unstructured":"Hu Y, Lei M, Ke G, Huang X, Peng X, Zhong L, Fu P. Metformin use and risk of all-cause mortality and cardiovascular events in patients with chronic kidney disease-a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2020, 11:559446. 10.3389\/fendo.2020.559446","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref36","article-title":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","unstructured":"UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998, 352:854-65.","journal-title":"Lancet"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jash.2014.01.007","article-title":"Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis","volume":"8","author":"Baker WL","year":"2014","unstructured":"Baker WL, Smyth LR, Riche DM, Bourret EM, Chamberlin KW, White WB. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens. 2014, 8:262-75.e9. 10.1016\/j.jash.2014.01.007","journal-title":"J Am Soc Hypertens"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.59556\/japi.71.0422","article-title":"SGLT2i as a first-line antihyperglycemic in the management of type 2 diabetes in the context of Indians: a systematic review and consensus","volume":"71","author":"Singh AK","year":"2023","unstructured":"Singh AK, Misra A, Das AK, et al.. SGLT2i as a first-line antihyperglycemic in the management of type 2 diabetes in the context of Indians: a systematic review and consensus. J Assoc Physicians India. 2023, 71:62-74. 10.59556\/japi.71.0422","journal-title":"J Assoc Physicians India"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-0978","article-title":"Durability of triple combination therapy versus stepwise addition therapy in patients with new-onset T2DM: 3-year follow-up of EDICT","volume":"44","author":"Abdul-Ghani M","year":"2021","unstructured":"Abdul-Ghani M, Puckett C, Adams J, et al.. Durability of triple combination therapy versus stepwise addition therapy in patients with new-onset T2DM: 3-year follow-up of EDICT. Diabetes Care. 2021, 44:433-9. 10.2337\/dc20-0978","journal-title":"Diabetes Care"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32131-2","article-title":"Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial","volume":"394","author":"Matthews DR","year":"2019","unstructured":"Matthews DR, Pald\u00e1nius PM, Proot P, et al.. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet. 2019, 394:1519-29. 10.1016\/S0140-6736(19)32131-2","journal-title":"Lancet"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2022.08.002","article-title":"American Association of Clinical Endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan-2022 update","volume":"28","author":"Blonde L","year":"2022","unstructured":"Blonde L, Umpierrez GE, Reddy SS, et al.. American Association of Clinical Endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan-2022 update. Endocr Pract. 2022, 28:923-1049. 10.1016\/j.eprac.2022.08.002","journal-title":"Endocr Pract"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2023.02.001","article-title":"American Association of Clinical Endocrinology consensus statement: comprehensive type 2 diabetes management algorithm - 2023 update","volume":"29","author":"Samson SL","year":"2023","unstructured":"Samson SL, Vellanki P, Blonde L, et al.. American Association of Clinical Endocrinology consensus statement: comprehensive type 2 diabetes management algorithm - 2023 update. Endocr Pract. 2023, 29:305-40. 10.1016\/j.eprac.2023.02.001","journal-title":"Endocr Pract"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S450994","article-title":"Efficacy and safety of DPP-4 inhibitors and metformin combinations in type 2 diabetes: a systematic literature review and network meta-analysis","volume":"17","author":"Chen R","year":"2024","unstructured":"Chen R, Li J, Chen D, et al.. Efficacy and safety of DPP-4 inhibitors and metformin combinations in type 2 diabetes: a systematic literature review and network meta-analysis. Diabetes Metab Syndr Obes. 2024, 17:2471-93. 10.2147\/DMSO.S450994","journal-title":"Diabetes Metab Syndr Obes"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1055\/a-1555-2797","article-title":"Effects of sitagliptin as monotherapy and add-on to metformin on weight loss among overweight and obese patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Janani L","year":"2021","unstructured":"Janani L, Bamehr H, Tanha K, Mirzabeigi P, Montazeri H, Tarighi P. Effects of sitagliptin as monotherapy and add-on to metformin on weight loss among overweight and obese patients with type 2 diabetes: a systematic review and meta-analysis. Drug Res (Stuttg). 2021, 71:477-88. 10.1055\/a-1555-2797","journal-title":"Drug Res (Stuttg)"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_202204_28611","article-title":"Efficacy and safety of combination therapy with vildagliptin and metformin vs. metformin monotherapy for type 2 diabetes mellitus therapy: a meta-analysis","volume":"26","author":"Ding Y","year":"2022","unstructured":"Ding Y, Liu Y, Qu Y, et al.. Efficacy and safety of combination therapy with vildagliptin and metformin vs. metformin monotherapy for type 2 diabetes mellitus therapy: a meta-analysis. Eur Rev Med Pharmacol Sci. 2022, 26:2802-17. 10.26355\/eurrev_202204_28611","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"ref46","article-title":"A ProspectIve, OpeN-Label, Randomized Study Comparing EffIcacy and Safety of Teneligliptin VErsus Sitagliptin in Indian Patients with Inadequately Controlled Type 2 Diabetes Mellitus: INSITES Study","volume":"67","author":"Mohan V","year":"2019","unstructured":"Mohan V, Ramu M, Poongothai S, Kasthuri S. A ProspectIve, OpeN-Label, Randomized Study Comparing EffIcacy and Safety of Teneligliptin VErsus Sitagliptin in Indian Patients with Inadequately Controlled Type 2 Diabetes Mellitus: INSITES Study. J Assoc Physicians India. 2019, 67:14-9.","journal-title":"J Assoc Physicians India"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2019.107860","article-title":"Efficacy and safety of evogliptin versus sitagliptin as an add-on therapy in Indian patients with type 2 diabetes mellitus inadequately controlled with metformin: a 24-week randomized, double-blind, non-inferiority, EVOLUTION INDIA study","volume":"157","author":"Ajmani AK","year":"2019","unstructured":"Ajmani AK, Agrawal A, Prasad BL, et al.. Efficacy and safety of evogliptin versus sitagliptin as an add-on therapy in Indian patients with type 2 diabetes mellitus inadequately controlled with metformin: a 24-week randomized, double-blind, non-inferiority, EVOLUTION INDIA study. Diabetes Res Clin Pract. 2019, 157:107860. 10.1016\/j.diabres.2019.107860","journal-title":"Diabetes Res Clin Pract"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14226","article-title":"Sodium-glucose co-transporter-2 inhibitors with and without metformin: a meta-analysis of cardiovascular, kidney and mortality outcomes","volume":"23","author":"Neuen BL","year":"2021","unstructured":"Neuen BL, Arnott C, Perkovic V, et al.. Sodium-glucose co-transporter-2 inhibitors with and without metformin: a meta-analysis of cardiovascular, kidney and mortality outcomes. Diabetes Obes Metab. 2021, 23:382-90. 10.1111\/dom.14226","journal-title":"Diabetes Obes Metab"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-80603-8","article-title":"Cardiovascular safety and efficacy of metformin-SGLT2i versus metformin-sulfonylureas in type 2 diabetes: systematic review and meta-analysis of randomized controlled trials","volume":"11","author":"Gebrie D","year":"2021","unstructured":"Gebrie D, Getnet D, Manyazewal T. Cardiovascular safety and efficacy of metformin-SGLT2i versus metformin-sulfonylureas in type 2 diabetes: systematic review and meta-analysis of randomized controlled trials. Sci Rep. 2021, 11:137. 10.1038\/s41598-020-80603-8","journal-title":"Sci Rep"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S193528","article-title":"SGLT2 inhibitors as add-on therapy to metformin for people with type 2 diabetes: a review of placebo-controlled trials in Asian versus non-Asian patients","volume":"13","author":"Scheen AJ","year":"2020","unstructured":"Scheen AJ. SGLT2 inhibitors as add-on therapy to metformin for people with type 2 diabetes: a review of placebo-controlled trials in Asian versus non-Asian patients. Diabetes Metab Syndr Obes. 2020, 13:2765-79. 10.2147\/DMSO.S193528","journal-title":"Diabetes Metab Syndr Obes"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-61590-6","article-title":"Dapagliflozin added to metformin reduces perirenal fat layer in type 2 diabetic patients with obesity","volume":"14","author":"Cuatrecasas G","year":"2024","unstructured":"Cuatrecasas G, De Cabo F, Coves MJ, et al.. Dapagliflozin added to metformin reduces perirenal fat layer in type 2 diabetic patients with obesity. Sci Rep. 2024, 14:10832. 10.1038\/s41598-024-61590-6","journal-title":"Sci Rep"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.3269","article-title":"Effect of dapagliflozin in patients with diabetes and heart failure with mildly reduced or preserved ejection fraction according to background glucose-lowering therapy: a pre-specified analysis of the DELIVER trial","volume":"26","author":"Lassen MC","year":"2024","unstructured":"Lassen MC, Ostrominski JW, Inzucchi SE, et al.. Effect of dapagliflozin in patients with diabetes and heart failure with mildly reduced or preserved ejection fraction according to background glucose-lowering therapy: a pre-specified analysis of the DELIVER trial. Eur J Heart Fail. 2024, 26:1539-48. 10.1002\/ejhf.3269","journal-title":"Eur J Heart Fail"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13294","article-title":"SGLT2 inhibitor plus DPP-4 inhibitor as combination therapy for type 2 diabetes: a systematic review and meta-analysis","volume":"20","author":"Li D","year":"2018","unstructured":"Li D, Shi W, Wang T, Tang H. SGLT2 inhibitor plus DPP-4 inhibitor as combination therapy for type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2018, 20:1972-6. 10.1111\/dom.13294","journal-title":"Diabetes Obes Metab"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-023-01504-3","article-title":"A randomized, double-blind, parallel-group Phase III trial investigating the glycemic efficacy and safety profile of fixed-dose combination dapagliflozin and linagliptin over linagliptin monotherapy in patients with inadequately controlled type 2 diabetes with metformin","volume":"15","author":"Jain A","year":"2024","unstructured":"Jain A, Vispute A, Dange A, et al.. A randomized, double-blind, parallel-group Phase III trial investigating the glycemic efficacy and safety profile of fixed-dose combination dapagliflozin and linagliptin over linagliptin monotherapy in patients with inadequately controlled type 2 diabetes with metformin. Diabetes Ther. 2024, 15:215-27. 10.1007\/s13300-023-01504-3","journal-title":"Diabetes Ther"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30086-5","article-title":"Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial","volume":"7","author":"Pollock C","year":"2019","unstructured":"Pollock C, Stef\u00e1nsson B, Reyner D, et al.. Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2019, 7:429-41. 10.1016\/S2213-8587(19)30086-5","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref56","article-title":"Efficacy and safety of a fixed dose combination of remogliflozin etabonate and vildagliptin in patients with type-2 diabetes mellitus: a randomized, active-controlled, double-blind, Phase III study","volume":"70","author":"Khaladkar K","year":"2022","unstructured":"Khaladkar K, Mohan B, Khaladkar K, Suryawanshi S, Barkatestrong\/Strong H. Efficacy and safety of a fixed dose combination of remogliflozin etabonate and vildagliptin in patients with type-2 diabetes mellitus: a randomized, active-controlled, double-blind, Phase III study. J Assoc Physicians India. 2022, 70:11-2.","journal-title":"J Assoc Physicians India"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1007\/s13410-024-01321-9","article-title":"A randomized, double-blind, active-controlled trial assessing the efficacy and safety of a fixed-dose combination (FDC) of MEtformin hydrochloride 1000 mg ER, SItagliptin phosphate 100 mg, and DApagliflozin propanediol 10 mg in Indian adults with type 2 diabetes: the MESIDA trial","volume":"44","author":"Singh AK","year":"2024","unstructured":"Singh AK, Sahay R, Gil N, et al.. A randomized, double-blind, active-controlled trial assessing the efficacy and safety of a fixed-dose combination (FDC) of MEtformin hydrochloride 1000 mg ER, SItagliptin phosphate 100 mg, and DApagliflozin propanediol 10 mg in Indian adults with type 2 diabetes: the MESIDA trial. Int J Diabetes Dev Ctries. 2024, 44:67-76. 10.1007\/s13410-024-01321-9","journal-title":"Int J Diabetes Dev Ctries"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02523-z","article-title":"Fixed-dose combination of dapagliflozin + sitagliptin + metformin in patients with type 2 diabetes Poorly controlled with metformin: phase 3, randomized comparison with dual combinations","volume":"40","author":"Sahay RK","year":"2023","unstructured":"Sahay RK, Giri R, Shembalkar JV, et al.. Fixed-dose combination of dapagliflozin + sitagliptin + metformin in patients with type 2 diabetes Poorly controlled with metformin: phase 3, randomized comparison with dual combinations. Adv Ther. 2023, 40:3227-46. 10.1007\/s12325-023-02523-z","journal-title":"Adv Ther"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1080\/03014460.2022.2072525","article-title":"Prevalence of hypertension among individuals with diabetes and its determinants: evidences from the National Family Health Survey 2015-16, India","volume":"49","author":"Santra A","year":"2022","unstructured":"Santra A, Mallick A. Prevalence of hypertension among individuals with diabetes and its determinants: evidences from the National Family Health Survey 2015-16, India. Ann Hum Biol. 2022, 49:133-44. 10.1080\/03014460.2022.2072525","journal-title":"Ann Hum Biol"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-S010","article-title":"10. Cardiovascular disease and risk management: standards of care in diabetes-2024","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2024","unstructured":"American Diabetes Association Professional Practice Committee. 10. Cardiovascular disease and risk management: standards of care in diabetes-2024. Diabetes Care. 2024, 47:S179-218. 10.2337\/dc24-S010","journal-title":"Diabetes Care"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-023-01092-z","article-title":"Efficacy and safety evaluation of SGLT2i on blood pressure control in patients with type 2 diabetes and hypertension: a new meta-analysis","volume":"15","author":"Zhang Q","year":"2023","unstructured":"Zhang Q, Zhou S, Liu L. Efficacy and safety evaluation of SGLT2i on blood pressure control in patients with type 2 diabetes and hypertension: a new meta-analysis. Diabetol Metab Syndr. 2023, 15:118. 10.1186\/s13098-023-01092-z","journal-title":"Diabetol Metab Syndr"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2024.03.001","article-title":"Effect of sodium-glucose cotransporter 2 inhibitors on the 24-hour ambulatory blood pressure in patients with type 2 diabetes mellitus and hypertension: an updated meta-analysis","volume":"30","author":"Iqbal F","year":"2024","unstructured":"Iqbal F, Shuja MH, Azam L, et al.. Effect of sodium-glucose cotransporter 2 inhibitors on the 24-hour ambulatory blood pressure in patients with type 2 diabetes mellitus and hypertension: an updated meta-analysis. Endocr Pract. 2024, 30:481-9. 10.1016\/j.eprac.2024.03.001","journal-title":"Endocr Pract"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.121.058103","article-title":"Efficacy and safety of dapagliflozin in type 2 diabetes according to baseline blood pressure: observations from DECLARE-TIMI 58 trial","volume":"145","author":"Furtado RH","year":"2022","unstructured":"Furtado RH, Raz I, Goodrich EL, et al.. Efficacy and safety of dapagliflozin in type 2 diabetes according to baseline blood pressure: observations from DECLARE-TIMI 58 trial. Circulation. 2022, 145:1581-91. 10.1161\/CIRCULATIONAHA.121.058103","journal-title":"Circulation"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa419","article-title":"A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial","volume":"41","author":"Brown AJ","year":"2020","unstructured":"Brown AJ, Gandy S, McCrimmon R, Houston JG, Struthers AD, Lang CC. A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial. Eur Heart J. 2020, 41:3421-32. 10.1093\/eurheartj\/ehaa419","journal-title":"Eur Heart J"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-07395-x","article-title":"Effect of SGLT-2 inhibitor, empagliflozin, on blood pressure reduction in Chinese elderly hypertension patients with type 2 diabetes and its possible mechanisms","volume":"12","author":"Cheng L","year":"2022","unstructured":"Cheng L, Fu Q, Zhou L, et al.. Effect of SGLT-2 inhibitor, empagliflozin, on blood pressure reduction in Chinese elderly hypertension patients with type 2 diabetes and its possible mechanisms. Sci Rep. 2022, 12:3525. 10.1038\/s41598-022-07395-x","journal-title":"Sci Rep"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12030772","article-title":"The effect of semaglutide on blood pressure in patients without diabetes: a systematic review and meta-analysis","volume":"12","author":"Kennedy C","year":"2023","unstructured":"Kennedy C, Hayes P, Salama S, Hennessy M, Fogacci F. The effect of semaglutide on blood pressure in patients without diabetes: a systematic review and meta-analysis. J Clin Med. 2023, 12:772. 10.3390\/jcm12030772","journal-title":"J Clin Med"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15529","article-title":"Glucagon-like peptide-1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: a meta-analysis and meta-regression","volume":"26","author":"Rivera FB","year":"2024","unstructured":"Rivera FB, Lumbang GN, Gaid DR, et al.. Glucagon-like peptide-1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: a meta-analysis and meta-regression. Diabetes Obes Metab. 2024, 26:2209-28. 10.1111\/dom.15529","journal-title":"Diabetes Obes Metab"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14108","article-title":"Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors as combination therapy for type 2 diabetes: a systematic review and meta-analysis","volume":"22","author":"Mantsiou C","year":"2020","unstructured":"Mantsiou C, Karagiannis T, Kakotrichi P, et al.. Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors as combination therapy for type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2020, 22:1857-68. 10.1111\/dom.14108","journal-title":"Diabetes Obes Metab"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-022-01516-6","article-title":"Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management","volume":"21","author":"Ma CX","year":"2022","unstructured":"Ma CX, Ma XN, Guan CH, Li YD, Mauricio D, Fu SB. Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management. Cardiovasc Diabetol. 2022, 21:74. 10.1186\/s12933-022-01516-6","journal-title":"Cardiovasc Diabetol"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-021-01344-0","article-title":"CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries","volume":"20","author":"Mosenzon O","year":"2021","unstructured":"Mosenzon O, Alguwaihes A, Leon JL, et al.. CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries. Cardiovasc Diabetol. 2021, 20:154. 10.1186\/s12933-021-01344-0","journal-title":"Cardiovasc Diabetol"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0263619","article-title":"Cardiovascular risk in newly diagnosed type 2 diabetes patients in India","volume":"17","author":"Unnikrishnan AG","year":"2022","unstructured":"Unnikrishnan AG, Sahay RK, Phadke U, et al.. Cardiovascular risk in newly diagnosed type 2 diabetes patients in India. PLoS One. 2022, 17:e0263619. 10.1371\/journal.pone.0263619","journal-title":"PLoS One"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad192","article-title":"2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes","volume":"44","author":"Marx N","year":"2023","unstructured":"Marx N, Federici M, Sch\u00fctt K, et al.. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023, 44:4043-140. 10.1093\/eurheartj\/ehad192","journal-title":"Eur Heart J"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino F","year":"2020","unstructured":"Cosentino F, Grant PJ, Aboyans V, et al.. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020, 41:255-323. 10.1093\/eurheartj\/ehz486","journal-title":"Eur Heart J"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(24)00102-5","article-title":"Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis","volume":"12","author":"Usman MS","year":"2024","unstructured":"Usman MS, Bhatt DL, Hameed I, et al.. Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2024, 12:447-61. 10.1016\/S2213-8587(24)00102-5","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-022-05773-8","article-title":"SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials balancing their risks and benefits","volume":"65","author":"Marilly E","year":"2022","unstructured":"Marilly E, Cottin J, Cabrera N, et al.. SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials balancing their risks and benefits. Diabetologia. 2022, 65:2000-10. 10.1007\/s00125-022-05773-8","journal-title":"Diabetologia"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.14355","article-title":"Systematic review of sodium-glucose cotransporter 2 inhibitors: a hopeful prospect in tackling heart failure-related events","volume":"10","author":"Aziri B","year":"2023","unstructured":"Aziri B, Begic E, Jankovic S, et al.. Systematic review of sodium-glucose cotransporter 2 inhibitors: a hopeful prospect in tackling heart failure-related events. ESC Heart Fail. 2023, 10:1499-530. 10.1002\/ehf2.14355","journal-title":"ESC Heart Fail"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2024.100679","article-title":"Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials","volume":"18","author":"Rivera FB","year":"2024","unstructured":"Rivera FB, Cruz LL, Magalong JV, et al.. Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials. Am J Prev Cardiol. 2024, 18:100679. 10.1016\/j.ajpc.2024.100679","journal-title":"Am J Prev Cardiol"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-023-02362-6","article-title":"GLP-1-ra and heart failure-related outcomes in patients with and without history of heart failure: an updated systematic review and meta-analysis","volume":"113","author":"Villaschi A","year":"2024","unstructured":"Villaschi A, Ferrante G, Cannata F, et al.. GLP-1-ra and heart failure-related outcomes in patients with and without history of heart failure: an updated systematic review and meta-analysis. Clin Res Cardiol. 2024, 113:898-909. 10.1007\/s00392-023-02362-6","journal-title":"Clin Res Cardiol"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-021-01366-8","article-title":"GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs","volume":"20","author":"Giugliano D","year":"2021","unstructured":"Giugliano D, Scappaticcio L, Longo M, et al.. GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs. Cardiovasc Diabetol. 2021, 20:189. 10.1186\/s12933-021-01366-8","journal-title":"Cardiovasc Diabetol"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-019-0293-y","article-title":"Dipeptidyl peptidase 4 (DPP-4) inhibitors and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM): a systematic review and meta-analysis","volume":"20","author":"Liu D","year":"2019","unstructured":"Liu D, Jin B, Chen W, Yun P. Dipeptidyl peptidase 4 (DPP-4) inhibitors and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM): a systematic review and meta-analysis. BMC Pharmacol Toxicol. 2019, 20:15. 10.1186\/s40360-019-0293-y","journal-title":"BMC Pharmacol Toxicol"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.18269","article-title":"Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial","volume":"321","author":"Rosenstock J","year":"2019","unstructured":"Rosenstock J, Perkovic V, Johansen OE, et al.. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA. 2019, 321:69-79. 10.1001\/jama.2018.18269","journal-title":"JAMA"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.15277\/bjd.2020.242","article-title":"Series: cardiovascular outcome trials for diabetes drugs sitagliptin and TECOS","volume":"20","author":"Fisher M","year":"2020","unstructured":"Fisher M. Series: cardiovascular outcome trials for diabetes drugs sitagliptin and TECOS. BJD. 2020, 20:55-7. 10.15277\/bjd.2020.242","journal-title":"BJD"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2015.173","article-title":"Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease","volume":"12","author":"Thomas MC","year":"2016","unstructured":"Thomas MC, Cooper ME, Zimmet P. Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease. Nat Rev Nephrol. 2016, 12:73-81. 10.1038\/nrneph.2015.173","journal-title":"Nat Rev Nephrol"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-023-01202-x","article-title":"Prevalence and predictors of chronic kidney disease among type 2 diabetic patients worldwide, systematic review and meta-analysis","volume":"15","author":"Fenta ET","year":"2023","unstructured":"Fenta ET, Eshetu HB, Kebede N, et al.. Prevalence and predictors of chronic kidney disease among type 2 diabetic patients worldwide, systematic review and meta-analysis. Diabetol Metab Syndr. 2023, 15:245. 10.1186\/s13098-023-01202-x","journal-title":"Diabetol Metab Syndr"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.4103\/2230-8210.157857","article-title":"An observational, cross-sectional study to assess the prevalence of chronic kidney disease in type 2 diabetes patients in India (START -India)","volume":"19","author":"Prasannakumar M","year":"2015","unstructured":"Prasannakumar M, Rajput R, Seshadri K, et al.. An observational, cross-sectional study to assess the prevalence of chronic kidney disease in type 2 diabetes patients in India (START -India). Indian J Endocrinol Metab. 2015, 19:520-3. 10.4103\/2230-8210.157857","journal-title":"Indian J Endocrinol Metab"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.7326\/M22-2904","article-title":"Diabetes management in chronic kidney disease: synopsis of the KDIGO 2022 clinical practice guideline update","volume":"176","author":"Navaneethan SD","year":"2023","unstructured":"Navaneethan SD, Zoungas S, Caramori ML, et al.. Diabetes management in chronic kidney disease: synopsis of the KDIGO 2022 clinical practice guideline update. Ann Intern Med. 2023, 176:381-7. 10.7326\/M22-2904","journal-title":"Ann Intern Med"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2022.06.008","article-title":"KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease","volume":"102","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group","year":"2022","unstructured":"Kidney Disease. Improving Global Outcomes (KDIGO) Diabetes Work Group: KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2022, 102:S1-S127. 10.1016\/j.kint.2022.06.008","journal-title":"Kidney Int"},{"key":"ref88","unstructured":"Type 2 diabetes in adults-management. (2022). Accessed. Sep 19, 2024: https:\/\/www.nice.org.uk\/guidance\/ng28\/resources\/type-2-diabetes-in-adults-management-pdf-1837338615493."},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","year":"2022","unstructured":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes. collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022, 400:1788-801. 10.1016\/S0140-6736(22)02074-8","journal-title":"Lancet"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2023-003836","article-title":"Effects of sodium-glucose cotransporter-2 (SGLT-2) inhibitors on serum uric acid levels in patients with chronic kidney disease: a systematic review and network meta-analysis","volume":"12","author":"Zhang L","year":"2024","unstructured":"Zhang L, Zhang F, Bai Y, Huang L, Zhong Y, Zhang X. Effects of sodium-glucose cotransporter-2 (SGLT-2) inhibitors on serum uric acid levels in patients with chronic kidney disease: a systematic review and network meta-analysis. BMJ Open Diabetes Res Care. 2024, 12:e003836. 10.1136\/bmjdrc-2023-003836","journal-title":"BMJ Open Diabetes Res Care"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink HJ","year":"2020","unstructured":"Heerspink HJ, Stef\u00e1nsson BV, Correa-Rotter R, et al.. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020, 383:1436-46. 10.1056\/NEJMoa2024816","journal-title":"N Engl J Med"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(21)00243-6","article-title":"Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial","volume":"9","author":"Jongs N","year":"2021","unstructured":"Jongs N, Greene T, Chertow GM, et al.. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021, 9:755-66. 10.1016\/S2213-8587(21)00243-6","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(20)30162-5","article-title":"Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial","volume":"8","author":"Cherney DZI","year":"2020","unstructured":"Cherney DZI, Dekkers CCJ, Barbour SJ, et al.. Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial. Lancet Diabetes Endocrinol. 2020, 8:582-93. 10.1016\/S2213-8587(20)30162-5","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer M","year":"2020","unstructured":"Packer M, Anker SD, Butler J, et al.. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020, 383:1413-24. 10.1056\/NEJMoa2022190","journal-title":"N Engl J Med"},{"key":"ref95","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington WG","year":"2023","unstructured":"Herrington WG, Staplin N, Wanner C, et al.. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023, 388:117-27. 10.1056\/NEJMoa2204233","journal-title":"N Engl J Med"},{"key":"ref96","doi-asserted-by":"publisher","DOI":"10.3390\/diseases12010014","article-title":"Safety and efficacy of GLP-1 receptor agonists in type 2 diabetes mellitus with advanced and end-stage kidney disease: a systematic review and meta-analysis","volume":"12","author":"Krisanapan P","year":"2024","unstructured":"Krisanapan P, Sanpawithayakul K, Pattharanitima P, et al.. Safety and efficacy of GLP-1 receptor agonists in type 2 diabetes mellitus with advanced and end-stage kidney disease: a systematic review and meta-analysis. Diseases. 2024, 12:14. 10.3390\/diseases12010014","journal-title":"Diseases"},{"key":"ref97","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15304","article-title":"Effect of glucagon-like peptide-1 receptor agonists on renal function: a meta-analysis of randomized controlled trials","volume":"88","author":"Simental-Mend\u00eda M","year":"2022","unstructured":"Simental-Mend\u00eda M, Linden-Torres E, S\u00e1nchez-Garc\u00eda A, Sahebkar A, Simental-Mend\u00eda LE. Effect of glucagon-like peptide-1 receptor agonists on renal function: a meta-analysis of randomized controlled trials. Br J Clin Pharmacol. 2022, 88:3566-76. 10.1111\/bcp.15304","journal-title":"Br J Clin Pharmacol"},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13847","article-title":"GLP-1 receptor agonists for prevention of cardiorenal outcomes in type 2 diabetes: an updated meta-analysis including the REWIND and PIONEER 6 trials","volume":"21","author":"Giugliano D","year":"2019","unstructured":"Giugliano D, Maiorino MI, Bellastella G, Longo M, Chiodini P, Esposito K. GLP-1 receptor agonists for prevention of cardiorenal outcomes in type 2 diabetes: an updated meta-analysis including the REWIND and PIONEER 6 trials. Diabetes Obes Metab. 2019, 21:2576-80. 10.1111\/dom.13847","journal-title":"Diabetes Obes Metab"},{"key":"ref99","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen SL","year":"2019","unstructured":"Kristensen SL, R\u00f8rth R, Jhund PS, et al.. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019, 7:776-85. 10.1016\/S2213-8587(19)30249-9","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref100","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-30643-7","article-title":"The effect of linagliptin on microalbuminuria in patients with diabetic nephropathy: a randomized, double blinded clinical trial","volume":"13","author":"Karimifar M","year":"2023","unstructured":"Karimifar M, Afsar J, Amini M, Moeinzadeh F, Feizi A, Aminorroaya A. The effect of linagliptin on microalbuminuria in patients with diabetic nephropathy: a randomized, double blinded clinical trial. Sci Rep. 2023, 13:3479. 10.1038\/s41598-023-30643-7","journal-title":"Sci Rep"},{"key":"ref101","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-024-02192-4","article-title":"Effectiveness and safety of the combination of sodium-glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of observational studies","volume":"23","author":"Ahmad A","year":"2024","unstructured":"Ahmad A, Sabbour H. Effectiveness and safety of the combination of sodium-glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of observational studies. Cardiovasc Diabetol. 2024, 23:99. 10.1186\/s12933-024-02192-4","journal-title":"Cardiovasc Diabetol"},{"key":"ref102","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2023.2182909","article-title":"Prevalence and associated factors of overweight and obesity among persons with type 2 diabetes in Africa: a systematic review and meta-analysis","volume":"55","author":"Ekpor E","year":"2023","unstructured":"Ekpor E, Akyirem S, Adade Duodu P. Prevalence and associated factors of overweight and obesity among persons with type 2 diabetes in Africa: a systematic review and meta-analysis. Ann Med. 2023, 55:696-713. 10.1080\/07853890.2023.2182909","journal-title":"Ann Med"},{"key":"ref103","doi-asserted-by":"publisher","DOI":"10.2147\/IJGM.S377463","article-title":"Prevalence and pattern of dyslipidemia and its associated factors among patients with type 2 diabetes mellitus in Jordan: a cross-sectional study","volume":"15","author":"Al Quran TM","year":"2022","unstructured":"Al Quran TM, Bataineh ZA, Al-Mistarehi AH, et al.. Prevalence and pattern of dyslipidemia and its associated factors among patients with type 2 diabetes mellitus in Jordan: a cross-sectional study. Int J Gen Med. 2022, 15:7669-83. 10.2147\/IJGM.S377463","journal-title":"Int J Gen Med"},{"key":"ref104","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-38275-7","article-title":"A systematic review and meta-analysis of the prevalence of dyslipidaemia among adults in Malaysia","volume":"13","author":"Mohamed-Yassin MS","year":"2023","unstructured":"Mohamed-Yassin MS, Rosman N, Kamaruddin KN, et al.. A systematic review and meta-analysis of the prevalence of dyslipidaemia among adults in Malaysia. Sci Rep. 2023, 13:11036. 10.1038\/s41598-023-38275-7","journal-title":"Sci Rep"},{"key":"ref105","doi-asserted-by":"publisher","DOI":"10.1016\/j.endinu.2019.04.010","article-title":"The prevalence and risk factors associated with dyslipidemia in type 2 diabetic patients in the autonomous Region of Cantabria","volume":"67","author":"D\u00edaz Vera AS","year":"2020","unstructured":"D\u00edaz Vera AS, Abell\u00e1n Alem\u00e1n J, Segura Fragoso A, et al.. The prevalence and risk factors associated with dyslipidemia in type 2 diabetic patients in the autonomous Region of Cantabria. Endocrinol Diabetes Nutr (Engl Ed). 2020, 67:102-12. 10.1016\/j.endinu.2019.04.010","journal-title":"Endocrinol Diabetes Nutr (Engl Ed)"},{"key":"ref106","doi-asserted-by":"publisher","DOI":"10.1186\/s13104-017-2465-4","article-title":"Prevalence and pattern of dyslipidemia in Nepalese individuals with type 2 diabetes","volume":"10","author":"Pokharel DR","year":"2017","unstructured":"Pokharel DR, Khadka D, Sigdel M, et al.. Prevalence and pattern of dyslipidemia in Nepalese individuals with type 2 diabetes. BMC Res Notes. 2017, 10:146. 10.1186\/s13104-017-2465-4","journal-title":"BMC Res Notes"},{"key":"ref107","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock J","year":"2021","unstructured":"Rosenstock J, Wysham C, Fr\u00edas JP, et al.. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet. 2021, 398:143-55. 10.1016\/S0140-6736(21)01324-6","journal-title":"The Lancet"},{"key":"ref108","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-023-01085-y","article-title":"Effects of SGLT-2 inhibitors on adipose tissue distribution in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials","volume":"15","author":"Wang X","year":"2023","unstructured":"Wang X, Wu N, Sun C, Jin D, Lu H. Effects of SGLT-2 inhibitors on adipose tissue distribution in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Diabetol Metab Syndr. 2023, 15:113. 10.1186\/s13098-023-01085-y","journal-title":"Diabetol Metab Syndr"},{"key":"ref109","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4985","article-title":"Effects of sodium glucose cotransporter 2 inhibitors on risk of dyslipidemia among patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"29","author":"Li D","year":"2020","unstructured":"Li D, Wu T, Wang T, Wei H, Wang A, Tang H, Song Y. Effects of sodium glucose cotransporter 2 inhibitors on risk of dyslipidemia among patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Pharmacoepidemiol Drug Saf. 2020, 29:582-90. 10.1002\/pds.4985","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref110","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.105068","article-title":"Effect of sodium-glucose co-transporter 2 inhibitors on lipid profile: a systematic review and meta-analysis of 48 randomized controlled trials","volume":"160","author":"S\u00e1nchez-Garc\u00eda A","year":"2020","unstructured":"S\u00e1nchez-Garc\u00eda A, Simental-Mend\u00eda M, Mill\u00e1n-Alan\u00eds JM, Simental-Mend\u00eda LE. Effect of sodium-glucose co-transporter 2 inhibitors on lipid profile: a systematic review and meta-analysis of 48 randomized controlled trials. Pharmacol Res. 2020, 160:105068. 10.1016\/j.phrs.2020.105068","journal-title":"Pharmacol Res"},{"key":"ref111","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2023.117236","article-title":"SGLT2-inhibition increases total, LDL, and HDL cholesterol and lowers triglycerides: meta-analyses of 60 randomized trials, overall and by dose, ethnicity, and drug type","volume":"394","author":"Bechmann LE","year":"2024","unstructured":"Bechmann LE, Emanuelsson F, Nordestgaard BG, Benn M. SGLT2-inhibition increases total, LDL, and HDL cholesterol and lowers triglycerides: meta-analyses of 60 randomized trials, overall and by dose, ethnicity, and drug type. Atherosclerosis. 2024, 394:117236. 10.1016\/j.atherosclerosis.2023.117236","journal-title":"Atherosclerosis"},{"key":"ref112","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116150","article-title":"Efficacy and safety of GLP-1RAs for people with obesity: a systematic review based on RCT and Bayesian network meta-analysis","volume":"171","author":"Li H","year":"2024","unstructured":"Li H, Yu G, Huang Q, Yang B, Nie J, Liu Y, Tu X. Efficacy and safety of GLP-1RAs for people with obesity: a systematic review based on RCT and Bayesian network meta-analysis. Biomed Pharmacother. 2024, 171:116150. 10.1016\/j.biopha.2024.116150","journal-title":"Biomed Pharmacother"},{"key":"ref113","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.32610","article-title":"Efficacy of semaglutide in treating obesity: a systematic review of randomized controlled trials (RCTs)","volume":"14","author":"Anam M","year":"2022","unstructured":"Anam M, Maharjan S, Amjad Z, et al.. Efficacy of semaglutide in treating obesity: a systematic review of randomized controlled trials (RCTs). Cureus. 2022, 14:e32610. 10.7759\/cureus.32610","journal-title":"Cureus"},{"key":"ref114","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076410","article-title":"Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis","volume":"384","author":"Yao H","year":"2024","unstructured":"Yao H, Zhang A, Li D, Wu Y, Wang CZ, Wan JY, Yuan CS. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ. 2024, 384:e076410. 10.1136\/bmj-2023-076410","journal-title":"BMJ"},{"key":"ref115","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-061807","article-title":"Efficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight\/obese patients with or without diabetes mellitus: a systematic review and network meta-analysis","volume":"13","author":"Ma H","year":"2023","unstructured":"Ma H, Lin YH, Dai LZ, Lin CS, Huang Y, Liu SY. Efficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight\/obese patients with or without diabetes mellitus: a systematic review and network meta-analysis. BMJ Open. 2023, 13:e061807. 10.1136\/bmjopen-2022-061807","journal-title":"BMJ Open"},{"key":"ref116","doi-asserted-by":"publisher","DOI":"10.3390\/life13041012","article-title":"A comprehensive review on weight loss associated with anti-diabetic medications","volume":"13","author":"Haddad F","year":"2023","unstructured":"Haddad F, Dokmak G, Bader M, Karaman R. A comprehensive review on weight loss associated with anti-diabetic medications. Life (Basel). 2023, 13:1012. 10.3390\/life13041012","journal-title":"Life (Basel)"},{"key":"ref117","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2024.2363838","article-title":"Lipid profile changes induced by glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a systematic review and network meta-analysis","volume":"17","author":"Chae Y","year":"2024","unstructured":"Chae Y, Kwon SH, Nam JH, Kang E, Im J, Kim HJ, Lee EK. Lipid profile changes induced by glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a systematic review and network meta-analysis. Expert Rev Clin Pharmacol. 2024, 17:721-9. 10.1080\/17512433.2024.2363838","journal-title":"Expert Rev Clin Pharmacol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/356889-expert-consensus-statement-on-simplified-glycemic-care-in-patients-with-type-2-diabetes-mellitus","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T03:44:54Z","timestamp":1751255094000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/356889-expert-consensus-statement-on-simplified-glycemic-care-in-patients-with-type-2-diabetes-mellitus"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,29]]},"references-count":117,"URL":"https:\/\/doi.org\/10.7759\/cureus.87002","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,29]]}}}